1
|
Donnette M, Osanno L, Giocanti M, Venton G, Farnault L, Berda-Haddad Y, Costello R, Caroline S, Ouafik L'H, Ciccolini J, Fanciullino R. Determination of 5-azacitidine in human plasma by LC-MS/MS: application to pharmacokinetics pilot study in MDS/AML patients. Cancer Chemother Pharmacol 2023; 91:231-238. [PMID: 36859512 DOI: 10.1007/s00280-023-04505-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 01/17/2023] [Indexed: 03/03/2023]
Abstract
PURPOSE Azacitidine (Vidaza®, AZA) is a mainstay for treating acute myeloid leukemia (AML) in patients unfit for standard induction and other myelodysplastic syndromes (MDS). However, only half of the patients usually respond to this drug and almost all patients will eventually relapse. Predictive markers for response to AZA are yet to be identified. AZA is metabolized in the liver by a single enzyme, cytidine deaminase (CDA). CDA is a ubiquitous enzyme coded by a highly polymorphic gene, with subsequent great variability in resulting activities in the liver. The quantitative determination of AZA in plasma is challenging due the required sensitivity and because of the instability in the biological matrix upon sampling, possibly resulting in erratic values. METHODS We have developed and validated following EMA standards a simple, rapid, and cost-effective liquid chromatography-tandem mass spectrometry method for the determination of azacitidine in human plasma. RESULTS After a simple and rapid precipitation step, analytes were successfully separated and quantitated over a 5-500 ng/mL range. The performance and reliability of this method were tested as part of an investigational study in MDS/AML patients treated with standard azacitidine (75 mg/m2 for 7 days a week every 28 days). CONCLUSION Overall, this new method meets the requirements of current bioanalytical guidelines and could be used to monitor drug levels in MDS/AML patients.
Collapse
Affiliation(s)
- Melanie Donnette
- Laboratoire de Pharmacocinétique, Faculté de Pharmacie de Marseille, SMARTc, Simulation and Modeling Adaptative Response for Therapeutics in Cancer, 27 Bd Jean Moulin, 13385, Marseille, France
- Faculté de Pharmacie de Marseille, COMPO, CRCM Inserm UMR 1068 & INRIA Sophia Antipolis, 27 Boulevard Jean-Moulin, 13385, Marseille, France
| | - Loic Osanno
- Laboratoire de Pharmacocinétique, Faculté de Pharmacie de Marseille, SMARTc, Simulation and Modeling Adaptative Response for Therapeutics in Cancer, 27 Bd Jean Moulin, 13385, Marseille, France
- Faculté de Pharmacie de Marseille, COMPO, CRCM Inserm UMR 1068 & INRIA Sophia Antipolis, 27 Boulevard Jean-Moulin, 13385, Marseille, France
| | - Madeleine Giocanti
- Laboratoire de Pharmacocinétique et Toxicologie, La Timone University Hospital of Marseille, 264 Rue Saint-Pierre, 13385, Marseille Cedex 5, France
| | - Geoffroy Venton
- Department of Hematology and Cellular Therapy, La Conception University Hospital of Marseille, 147 Boulevard Baille, 13005, Marseille, France
| | - Laure Farnault
- Department of Hematology and Cellular Therapy, La Conception University Hospital of Marseille, 147 Boulevard Baille, 13005, Marseille, France
| | - Yael Berda-Haddad
- Laboratoire de Biologie Medicale, La Conception University Hospital of Marseille, 147 Boulevard Baille, 13005, Marseille, France
| | - Régis Costello
- Department of Hematology and Cellular Therapy, La Conception University Hospital of Marseille, 147 Boulevard Baille, 13005, Marseille, France
| | - Solas Caroline
- Laboratoire de Pharmacocinétique et Toxicologie, La Timone University Hospital of Marseille, 264 Rue Saint-Pierre, 13385, Marseille Cedex 5, France
| | - L 'Houcine Ouafik
- Laboratoire de Transfert en Oncologie Biologie, Nord University Hispoital of Marseille, Chemin des Bourrely, 13915, Marseille cedex 20, France
| | - Joseph Ciccolini
- Laboratoire de Pharmacocinétique, Faculté de Pharmacie de Marseille, SMARTc, Simulation and Modeling Adaptative Response for Therapeutics in Cancer, 27 Bd Jean Moulin, 13385, Marseille, France
- Faculté de Pharmacie de Marseille, COMPO, CRCM Inserm UMR 1068 & INRIA Sophia Antipolis, 27 Boulevard Jean-Moulin, 13385, Marseille, France
- Laboratoire de Pharmacocinétique et Toxicologie, La Timone University Hospital of Marseille, 264 Rue Saint-Pierre, 13385, Marseille Cedex 5, France
| | - Raphaëlle Fanciullino
- Laboratoire de Pharmacocinétique, Faculté de Pharmacie de Marseille, SMARTc, Simulation and Modeling Adaptative Response for Therapeutics in Cancer, 27 Bd Jean Moulin, 13385, Marseille, France.
- Faculté de Pharmacie de Marseille, COMPO, CRCM Inserm UMR 1068 & INRIA Sophia Antipolis, 27 Boulevard Jean-Moulin, 13385, Marseille, France.
- Unit Pharmacy Hospital of Conception, University Hospital of Marseille, 147 Boulevard Baille, 13005, Marseille, France.
| |
Collapse
|
3
|
Li Y, Zhang X, Bai X, Li X, Jiang Q, Zhang T. A sensitive, high-throughput, and eco-friendly analysis of daidzein and its valine carbamate prodrug in rat plasma by supercritical fluid chromatography with tandem mass spectrometry. J Sep Sci 2018; 41:3250-3257. [DOI: 10.1002/jssc.201800430] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2018] [Revised: 06/28/2018] [Accepted: 07/03/2018] [Indexed: 12/23/2022]
Affiliation(s)
- Yingchao Li
- Department of Pharmaceutical Analysis, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang P. R. China
| | - Xingxing Zhang
- Department of Pharmaceutical Analysis, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang P. R. China
| | - Xiaochen Bai
- Department of Pharmaceutical Analysis, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang P. R. China
| | - Xiaoting Li
- Department of Pharmaceutical Analysis, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang P. R. China
| | - Qikun Jiang
- Wuya College of Innovation; Shenyang Pharmaceutical University; Shenyang P. R. China
| | - Tianhong Zhang
- Department of Pharmaceutical Analysis, School of Pharmacy; Shenyang Pharmaceutical University; Shenyang P. R. China
| |
Collapse
|
4
|
Enantioselective supercritical fluid chromatography–tandem mass spectrometry method for simultaneous estimation of risperidone and its 9-hydroxyl metabolites in rat plasma. Bioanalysis 2017; 9:1739-1750. [DOI: 10.4155/bio-2017-0168] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Aim: Objective of the current work was to develop a ‘green chemistry’ compliant selective and sensitive supercritical fluid chromatography–tandem mass spectrometry method for simultaneous estimation of risperidone (RIS) and its chiral metabolites in rat plasma. Methodology & results: Agilent 1260 Infinity analytical supercritical fluid chromatography system resolved RIS and its chiral metabolites within runtime of 6 min using a gradient chromatography method. Using a simple protein precipitation sample preparation followed by mass spectrometric detection achieved a sensitivity of 0.92 nM (lower limit of quantification). With linearity over four log units (0.91–7500 nM), the method was found to be selective, accurate, precise and robust. Conclusion: The method was validated and was successfully applied for simultaneous estimation of RIS and 9-hydroxyrisperidone metabolites (R & S individually) after intravenous and per oral administration to rats.
Collapse
|
6
|
The studies of PLGA nanoparticles loading atorvastatin calcium for oral administration in vitro and in vivo. Asian J Pharm Sci 2016; 12:285-291. [PMID: 32104340 PMCID: PMC7032215 DOI: 10.1016/j.ajps.2016.08.006] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2016] [Revised: 08/01/2016] [Accepted: 08/21/2016] [Indexed: 11/24/2022] Open
Abstract
A biodegradable poly(lactic-co-glycolic acid) loading atorvastatin calcium (AC) nanoparticles (AC-PLGA-NPs) were prepared by probe ultrasonication and evaporation method aiming at improving the oral bioavailability of AC. The effects of experimental parameters, including stabilizer species, stabilizer concentration and pH of aqueous phase, on particle size were also evaluated. The resultant nanoparticles were in spherical shape with an average diameter of 174.7 nm and a narrow particle size distribution. And the drug loading and encapsulation efficiency were about 8% and 71%, respectively. The particle size and polydispersion were almost unchanged in 10 days. The release curves of AC-PLGA-NPs in vitro displaying sustained release characteristics indicated that its release mechanisms were matrix erosion and diffusion. The pharmacokinetic study in vivo revealed that the Cmax and AUC0-∞ of AC-PLGA-NPs in rats were nearly 3.7-fold and 4.7-fold higher than that of pure atorvastatin calcium suspension. Our results demonstrated that the delivery of AC-PLGA-NPs could be a promising approach for the oral delivery of AC for enhanced bioavailability.
Collapse
|